Angiotensin II-mediated endothelial dysfunction: Role of poly(ADP-ribose) polymerase activation

Molecular Medicine

Volumn 10, Issue 1-6, 2004, Pages 28-35

  Szabó, Csaba ^a,b   Pacher, Pál ^a   Zsengellér, Zsuzsanna ^a   Vaslin, Anne ^a   Komjáti, Katalin ^a,b   Benkö, Rita ^a,b   Chen, Min ^a   Mabley, Jon G ^a   Kollai, Márk ^b  

^a INOTEK CORPORATION   (United States)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; APOCYNIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENZYME INHIBITOR; INO 1001; LOSARTAN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; N(G) NITROARGININE METHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDIZING AGENT; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECEPTOR SUBTYPE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME ACTIVATION; ENZYME INHIBITION; HEART; HYPERTENSION; KIDNEY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELLS, CULTURED; ENALAPRIL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; MUSCLE RELAXATION; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; VASCULAR DISEASES;

EID: 7444234222     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Virag L, Szabo C. (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54:375-429.
2. Hassa PO, Hottiger MO. (2002) The functional role of poly(ADP-ribose) polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell. Mol. Life Sci. 59:1534-53.
3. Drexler H, Harnig B. (1999) Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 31:51-60.
4. Wolf G. (2000) Free radical production and angiotensin. Curr. Hypertens. Rep. 2:167-73.
5. Singh BM, Mehta JL. (2003) Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch. Intern. Med. 163:1296-304.
6. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. (2003) The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet. Med. 20:607-21.
7. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. (1997) Role of superoxide in angiotensin II-induced but not catecholamine- induced hypertension. Circulation 95:588-93.
8. Wang D, Chen Y, Chabrashvili T, Aslam S, Barrego Candle LJ, Umans JG, Wilcox CS. (2003) Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin II of afferent arterioles from rabbits infused with angiotensin II. J. Am. Soc. Nephrol. 14:2783-9.
9. Rueckschloss U, Duerrschmidt N, Marawietz H. (2003) NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid. Redox. Signal. 5:171-80.
10. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, Harrison DG. (2002) Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40:511-5.
11. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. (2000) Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J. 14:271-8.
12. Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, Bauer JA. (2003) Effects of angiotensin II on vascular endothelial cells: formation of receptor-mediated reactive nitrogen species. Biochem. Pharmacol. 65:1189-97.
13. Jagtap P et al. (2002) Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit. Care Med. 30:1071-82.
14. Garcia Soriano F et al. (2001) Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat. Med. 7:108-13.
15. Shimoda K et al. (2003) Effect of poly (ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am. J. Physiol. Lung Cell. Mol. Physiol. 285:240-9.
16. Khan TA et al. (2003) Poly (ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J. Am. Coll. Surg. 197:270-7.
17. Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C. (2002) Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J. Am. Coll. Cardiol. 40:1006-16.
18. Pacher P et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896-904.
19. Pacher P, Mabley JG, Soriano FG, Liaudet L, Szabo C. (2002) Activation of poly (ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int. J. Mol. Med. 9:659-64.
20. Szabo C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. (1997) Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J. Clin. Invest. 100:723-35.
21. Cuzzocrea S et al. (1997) Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br. J. Pharmacol. 121:1065-74.
22. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. (2001) Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. 89:684-91.
23. Zhang H et al. (1999) Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH- oxidases. Cardiovasc. Res. 44:215-22.
24. Pueyo ME et al. (2000) Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 20:645-51.
25. Mervaala EM et al. (2001) Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 37:414-8.
26. Cai H et al. (2002) NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J. Biol. Chem. 277:48311-7.
27. Mollnau H et al. (2002) Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90:58-65.
28. Goto K, Fujii K, Onaka U, Abe I, Fujishima M. (2000) Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 36:575-80.
29. Raasch W et al. (2002) Regression of ventricular and vascular hypertrophy: are there differences between structurally different ACE inhibitors? J. Hypertens. 20:2495-504.
30. Ji Y, Huang Y, Han Y, Xu Y, Ferra A. (2003) Cardiac effects of amilaride and of enalapril in the spontaneously hypertensive rat. J Hypertens. 21:1583-9.
31. Go YM et al. (1999) Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH(2)-terminal kinase. Am. J. Physiol. 277:1647-53.
32. Silacci P, Desgeorges A, Mazzolai L, Chambaz C, Hayoz D. (2001) Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 38:1162-6.
33. Fleming I, Busse R. (2003) Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:1-12.
34. Tham DM et al. (2002) Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics 11:21-30.
35. Castanza A et al. (2003) Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J. Cell. Physiol. 195:402-10.